Wednesday, November 25, 2020

Altimmune Inc. [ALT] Revenue clocked in at $5.10 million, up 276.19% YTD: What’s Next?

Must read

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Tesla, Inc. (TSLA) Joins S&P 500;Morgan Stanley Raises EV giant Price Target

Wall Street analyst goes bullish on Musk’s EV maker as they see high-margin in firm’s potential software and services segment. Moreover, Tesla’s inclusion in...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Dolby Labs (DLB) Stock Marked 52-Week High On Tuesday, Expecting Growth In Current Quarter

Dolby Laboratories Inc. (NYSE: DLB), which develops audio and video technology broadcasting solutions, published a fourth quarter update last week. The business has been...

Altimmune Inc. [NASDAQ: ALT] price surged by 17.52 percent to reach at $1.06. A sum of 2742098 shares traded at recent session while its average daily volume was at 2.63M shares. Altimmune Inc. shares reached a high of $7.4499 and dropped to a low of $5.75 until finishing in the latest session at $7.11.

The one-year ALT stock forecast points to a potential upside of 45.31.


Daily trading lessons right to your inbox

Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.

GET FREE LESSON outside the norm.

Sponsored


Guru’s Opinion on Altimmune Inc. [ALT]:

ROTH Capital have made an estimate for Altimmune Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 24, 2020. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on July 19, 2019, representing the official price target for Altimmune Inc. stock. Previously, the target price had yet another raise to $6, while Piper Jaffray analysts kept a Overweight rating on ALT stock.

The Average True Range (ATR) for Altimmune Inc. is set at 1.02, with the Price to Sales ratio for ALT stock in the period of the last 12 months amounting to 27.99. The Price to Book ratio for the last quarter was 2.57, with the Price to Cash per share for the same quarter was set at 1.64.

ALT Stock Performance Analysis:

Altimmune Inc. [ALT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.83. With this latest performance, ALT shares gained by 92.16% in over the last four-week period, additionally plugging by 288.52% over the last 6 months – not to mention a rise of 202.55% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALT stock in for the last two-week period is set at 56.68, with the RSI for the last a single of trading hit 52.98, and the three-weeks RSI is set at 59.11 for Altimmune Inc. [ALT]. The present Moving Average for the last 50 days of trading for this stock 4.70, while it was recorded at 6.83 for the last single week of trading, and 2.73 for the last 200 days.

Insight into Altimmune Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Altimmune Inc. [ALT] shares currently have an operating margin of -293.63. Altimmune Inc.’s Net Margin is presently recorded at -353.71.

Return on Total Capital for ALT is now -35.43, given the latest momentum, and Return on Invested Capital for the company is -42.83. Return on Equity for this stock declined to -43.74, with Return on Assets sitting at -37.72. When it comes to the capital structure of this company, Altimmune Inc. [ALT] has a Total Debt to Total Equity ratio set at 3.83. Additionally, ALT Total Debt to Total Capital is recorded at 3.69, with Total Debt to Total Assets ending up at 3.23. Long-Term Debt to Equity for the company is recorded at 3.26, with the Long-Term Debt to Total Capital now at 3.14.

Reflecting on the efficiency of the workforce at the company, Altimmune Inc. [ALT] managed to generate an average of -$820,805 per employee. Receivables Turnover for the company is 1.90 with a Total Asset Turnover recorded at a value of 0.11.Altimmune Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.60 and a Current Ratio set at 6.60.

ALT Stock EPS

With the latest financial reports released by the company, Altimmune Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALT.

Altimmune Inc. [ALT] Insider Position Details

There are presently around $10 million, or 8.10% of ALT stock, in the hands of institutional investors. The top three institutional holders of ALT stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 617,007, which is approximately 255.929% of the company’s market cap and around 10.00% of the total institutional ownership; VANGUARD GROUP INC, holding 580,709 shares of the stock with an approximate value of $3.51 million in ALT stocks shares; and WINTON GROUP LTD, currently with $0.57 million in ALT stock with ownership of nearly -3.822% of the company’s market capitalization.

Positions in Altimmune Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 15 institutional holders increased their position in Altimmune Inc. [NASDAQ:ALT] by around 506,930 shares. Additionally, 14 investors decreased positions by around 218,525 shares, while 8 investors held positions by with 873,366 shares. The mentioned changes placed institutional holdings at 1,598,821 shares, according to the latest SEC report filing. ALT stock had 11 new institutional investments in for a total of 12,641 shares, while 8 institutional investors sold positions of 156,676 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Oil And Gold Drooped On Thursday, Markets Stimulates On Budget Support Plan

On Thursday, WTI oil dropped 0.2% to $41.74, while gold dropped 0.7% to $1,861.50 an ounce. Domestic oil inventories for the week ended November...

Tesla, Inc. (TSLA) Joins S&P 500;Morgan Stanley Raises EV giant Price Target

Wall Street analyst goes bullish on Musk’s EV maker as they see high-margin in firm’s potential software and services segment. Moreover, Tesla’s inclusion in...

Teledyne Technologies (TDY) Stock Just Missed Its 52-Week High On Wednesday

The American technology corporation Teledyne Technologies Incorporated (TDY) has won a contract of $85 million to supply components for the U.S. lunar program. As a...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.